PL2444103T3 - Szczepionka przeciwko rakowi szyjki macicy - Google Patents

Szczepionka przeciwko rakowi szyjki macicy

Info

Publication number
PL2444103T3
PL2444103T3 PL09846240T PL09846240T PL2444103T3 PL 2444103 T3 PL2444103 T3 PL 2444103T3 PL 09846240 T PL09846240 T PL 09846240T PL 09846240 T PL09846240 T PL 09846240T PL 2444103 T3 PL2444103 T3 PL 2444103T3
Authority
PL
Poland
Prior art keywords
vaccine
cervical cancer
cervical
cancer
Prior art date
Application number
PL09846240T
Other languages
English (en)
Inventor
Hong-Jin Kim
Na Gyong Lee
Yang-Je Cho
Jin-Wook Jang
Hyoung Jin Kim
Kwang Sung Kim
Original Assignee
Eyegene Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43356558&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2444103(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eyegene Inc. filed Critical Eyegene Inc.
Publication of PL2444103T3 publication Critical patent/PL2444103T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
PL09846240T 2009-06-19 2009-10-20 Szczepionka przeciwko rakowi szyjki macicy PL2444103T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20090055179 2009-06-19
EP09846240.1A EP2444103B1 (en) 2009-06-19 2009-10-20 Vaccine for cervical cancer
PCT/KR2009/006062 WO2010147268A1 (ko) 2009-06-19 2009-10-20 자궁경부암 백신

Publications (1)

Publication Number Publication Date
PL2444103T3 true PL2444103T3 (pl) 2018-05-30

Family

ID=43356558

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09846240T PL2444103T3 (pl) 2009-06-19 2009-10-20 Szczepionka przeciwko rakowi szyjki macicy

Country Status (11)

Country Link
US (1) US9566323B2 (pl)
EP (1) EP2444103B1 (pl)
JP (1) JP5758385B2 (pl)
KR (3) KR101181907B1 (pl)
CN (2) CN102215861B (pl)
AU (1) AU2009348078B2 (pl)
BR (1) BRPI0924981B1 (pl)
MX (1) MX2011013566A (pl)
PL (1) PL2444103T3 (pl)
TR (1) TR201802597T4 (pl)
WO (1) WO2010147268A1 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7999085B2 (en) * 2007-01-09 2011-08-16 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of protein by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
KR20120068647A (ko) * 2010-12-18 2012-06-27 아이진 주식회사 개선된 면역반응을 유도하는 백신
CN103717741B (zh) * 2011-06-15 2016-04-13 中央大学校产学协力团 用于提高人乳头瘤病毒l1蛋白产量的方法
CN103890177B (zh) * 2011-12-01 2016-03-09 开普敦大学 Hpv嵌合颗粒
KR101452830B1 (ko) * 2012-04-06 2014-10-21 아이진 주식회사 두 가지 항암물질을 동시에 제공하는 대장균 균주
KR101559622B1 (ko) 2012-07-30 2015-10-13 중앙대학교 산학협력단 인유두종바이러스 바이러스 유사입자의 고효율 정제방법
WO2014046410A1 (ko) * 2012-09-20 2014-03-27 중앙대학교 산학협력단 노다바이러스의 바이러스 유사입자의 생산방법, 이를 발현하는 효모 세포주 및 이를 포함하는 백신 조성물
KR20140060053A (ko) * 2012-11-09 2014-05-19 아이진 주식회사 인플루엔자 백신용 면역증강제
EP3191505A2 (en) * 2014-09-11 2017-07-19 Cadila Healthcare Limited Superior human papilloma virus antigens with superior immunological properties and vaccine containing it
CA2965498A1 (en) 2014-10-24 2016-04-28 Hpvvax, Llc. Compositions and uses of a papilloma virus (hpv) vaccine for the treatment of hpv related cancer and skin lesions
US10799574B2 (en) 2014-10-24 2020-10-13 Hpvvax. Llc Method and composition for treating cancer or skin lesion using a vaccine
WO2016104923A1 (ko) * 2014-12-26 2016-06-30 아이진 주식회사 인유두종 바이러스의 바이러스 유사 입자 제조방법
WO2018080253A1 (ko) * 2016-10-31 2018-05-03 아이진 주식회사 면역반응 조절물질 및 양이온성 리포좀을 포함하는 면역증강용 조성물 및 이의 용도
US10918709B2 (en) 2016-10-31 2021-02-16 Eyegene Inc. Immune modulator and vaccine composition containing the same

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1359156B1 (en) 1991-07-19 2007-03-07 University of Queensland Vaccine against Human Papillomavirus (Type 18)
US5618536A (en) 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
ES2264126T3 (es) * 1994-05-16 2006-12-16 MERCK & CO., INC. Vacunas contra el papilomavirus.
US5888516A (en) 1994-05-16 1999-03-30 Merck & Co. Inc. Recombinant papillomavirus vaccines
AR004464A1 (es) * 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
US6685949B1 (en) * 1998-01-13 2004-02-03 The United States Of America As Represented By The Department Of Health & Human Services Lipooligosaccharide based vaccine for prevention of moraxella (branhamella)catarrhalis infections in humans
GB9907553D0 (en) * 1999-04-01 1999-05-26 Cantab Pharma Res Purification of biological preparations
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
KR100423480B1 (ko) * 2001-11-20 2004-03-18 삼성전자주식회사 복수의 토너농도센서를 가지는 프린터 및 그의토너공급제어방법
KR100456681B1 (ko) * 2002-05-22 2004-11-10 주식회사 대웅 박테리아의 염색체 ｄｎａ 파쇄물과 비독성리포폴리사카라이드를 포함하는 면역강화 및 조절 조성물
PT1572233E (pt) * 2002-12-20 2011-06-07 Glaxosmithkline Biolog Sa Utilização de hpv16 e hpv18 como vacina contra um ou mais de tipos de hpv oncogénicos 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
UA85377C2 (ru) * 2002-12-20 2009-01-26 Глаксосмітклайн Байолоджикалз Са Применение композиции, содержащей вирусоподобные частички hpv16 і hpv18 при приготовлении медикамента для профилактики инфекции и/или болезни, вызванной группой hpv онкогенных типов, способы индуцирования иммунной реакции, профилактики инфекции и/или болезни, профилактики в популяции субъектов инфекции вызванных одной или несколькими группами онкогенных типов hpv, вакцинная композиция, которая включает hpv16 і нр18
US7368537B2 (en) * 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection
MY140664A (en) 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast
GB0323968D0 (en) * 2003-10-13 2003-11-19 Glaxosmithkline Biolog Sa Immunogenic compositions
GB0323965D0 (en) * 2003-10-13 2003-11-19 Glaxosmithkline Biolog Sa Immunogenic compositions
KR20070029254A (ko) * 2004-06-16 2007-03-13 글락소스미스클라인 바이오로지칼즈 에스.에이. Ｈｐｖ 16과 ｈｐｖ 18 및 적어도 ｈｐｖ 31, 45 또는52로부터 선택된 또 다른 ｈｐｖ 유형에 대한 백신
AR054259A1 (es) * 2005-04-26 2007-06-13 Glaxosmithkline Biolog Sa Vacuna contra virus de papiloma humano (hpv)
MX2007013475A (es) * 2005-04-26 2008-04-02 Glaxosmithkline Biolog Sa Vacuna.
KR100740237B1 (ko) 2005-05-10 2007-07-18 아이진 주식회사 올리고뉴클레오타이드 및 비독성 다당체를 포함하는면역보조제
US20090035330A1 (en) * 2005-05-19 2009-02-05 Marianne Dewerchin Vaccine Composition Comprising B-Subunit Of E. coli Heat Toxin And An Antigen And An Adjuvant
CA2608515A1 (en) * 2005-06-01 2007-05-10 Dow Global Technolgies Inc. Production of multivalent virus like particles
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
EP1986664A4 (en) * 2006-02-01 2009-07-22 Eyegene Inc COMPOSITION FOR THE TREATMENT OF CANCER WITH OLIGONUCLEOTIDES AND NON-TOXIC LPS

Also Published As

Publication number Publication date
KR101345205B1 (ko) 2013-12-27
CN102215861B (zh) 2014-10-08
AU2009348078B2 (en) 2013-03-14
TR201802597T4 (tr) 2018-03-21
KR20100136889A (ko) 2010-12-29
BRPI0924981B1 (pt) 2022-02-08
BRPI0924981A2 (pt) 2016-03-15
WO2010147268A1 (ko) 2010-12-23
AU2009348078A1 (en) 2011-12-15
CN104288763A (zh) 2015-01-21
EP2444103B1 (en) 2017-12-20
CN104288763B (zh) 2018-03-06
KR20130083426A (ko) 2013-07-22
US20120100169A1 (en) 2012-04-26
KR101181907B1 (ko) 2012-09-11
KR101595779B1 (ko) 2016-02-19
CN102215861A (zh) 2011-10-12
EP2444103A4 (en) 2013-12-18
US9566323B2 (en) 2017-02-14
JP2012530488A (ja) 2012-12-06
MX2011013566A (es) 2012-06-28
JP5758385B2 (ja) 2015-08-05
KR20120083263A (ko) 2012-07-25
EP2444103A1 (en) 2012-04-25

Similar Documents

Publication Publication Date Title
ZA201109164B (en) Vaccine
GB0905570D0 (en) Combined vaccines
EP2519196A4 (en) WOMB-SPACER
ZA201204050B (en) Vaccination syringe
IL215764A0 (en) Adjuvant cancer therapy
GB201006165D0 (en) Vaccine
IL214257A0 (en) Peptides for vaccine
GB201003293D0 (en) Cancer vaccine
EP2346531A4 (en) ANTITUMOR VACCINE
GB0907935D0 (en) Vaccines
IL216102A0 (en) Combined measles-malaria vaccine
GB0910751D0 (en) Prostate cancer vaccine
GB201000522D0 (en) Vaccine
ZA201201387B (en) Bovine herpesvirus vaccine
GB0921088D0 (en) Prostate Cancer DNA Vaccine
HRP20180744T1 (hr) Terapeutska cjepiva
GB201013006D0 (en) Vaccine
IL217194A0 (en) Vaccine
EP2416807A4 (en) NEW STRATEGIES FOR IMPROVED CANCER VACCINES
GB0914545D0 (en) Vaccine
ZA201107971B (en) Combined measles-malaria vaccine
GB0909145D0 (en) Vaccines
GB0909146D0 (en) Vaccines
GB0909144D0 (en) Vaccines
GB0909147D0 (en) Vaccines